Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study (Q73783125)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Robert Haddad

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A Dimitrios Colevas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Jeffrey F Krane

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Dennis Cooper

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Bonnie Glisson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Philip C Amrein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Linda Weeks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Rosemary Costello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Marshall Posner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

724-727

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

Malignant salivary tumors--analysis of prognostic factors and survival

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Salivary neoplasms: overview of a 35-year experience with 2,807 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

HER-2/neu expression: a major prognostic factor in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-8375%2803%2900097-6

7 January 2021

10.1016/S1368-8375(03)00097-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12907212%20AND%20SRC:MED&resulttype=core&format=json